Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Publication Type:

Journal Article

Source:

The New England journal of medicine, Volume 366, Issue 26, p.2455-65 (2012)

Keywords:

2012, Center-Authored Paper, Clinical Research Division, June 2012, Shared Resources, Specimen Processing Core Facility

Abstract:

Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models.